Pancreatic Cancer UK welcomes the results of randomized phase II trial comparing gemcitabine with gemcitabine plus AGS-1C4D4 in patients with metastatic pancreatic cancer, which is being presented at ASCO. The trial suggests that the combination of the human monoclonal antibody AGS-1C4D4 with gemcitabine may give a moderate improvement in survival in patients with advanced pancreatic cancer. These are early stage trial results but we would welcome further research into the AGS-1C4D4 compound to investigate whether it could have a place in the treatment of pancreatic cancer. It is vital that more research is undertaken into treatments that improve pancreatic cancer patients’ chances of survival and quality of life.
Click here to view the full abstract http://abstract.asco.org/AbstView_102_82420.html
This forum contains news that Pancreatic Cancer UK and forum users have shared over the years.
1 post • Page 1 of 1